Skip to main content
SpringerLink
Log in

Monitoring Anticoagulation

  • Chapter
  • First Online:
Transfusion Practice in Clinical Neurosciences

  • 662 Accesses

Abstract

Monitoring coagulation is recommended only in specific situation, especially if standardised tests are available, which serves multiple purposes such as efficacy, assess bleeding, use of antidotes, and aid in drug selection. Coagulation assays may provide qualitative or quantitative assessment of the drug used. Laboratory measurements are dependent on several patient factors such as age, time when the last dose was taken, half-life and other factors affecting pharmacokinetics for the appropriate interpretation of the test results. Clinical monitoring along with noncoagulation laboratory monitoring also play a major role in many patient scenarios. This chapter gives information on the physiology, pharmacology and monitoring of anticoagulation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005;118(6):612–7.

    Article  Google Scholar 

  2. Conway SE, Hwang AY, Ponte CD, Gums JG. Laboratory and clinical monitoring of direct acting oral anticoagulants: what clinicians need to know. Pharmacotherapy. 2017;37(2):236–48.

    Article  Google Scholar 

  3. Beshay JE, Morgan H, Madden C, Wengui Y, Sarode R. Emergency reversal of anticoagulation and antiplatelet therapies in neurosurgical patients. J Neurosurg. 2010;112:307–18.

    Article  CAS  Google Scholar 

  4. Oranmore-Brown C, Griffiths R. Anticoagulants and the perioperative period. Continuing education in anaesthesia. Crit Care Pain. 2006;6(4):156–9.

    Google Scholar 

  5. Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM. Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost. 2010;104:1106–15.

    Article  CAS  Google Scholar 

  6. Shamoun F, Obeid H, Ramakrishna H. Novel anticoagulants in atrial fibrillation: monitoring, reversal and perioperative management. BioMed Res Int 2015; Article ID 424031, 8 pages.

    Google Scholar 

  7. Orme R, Judge HM, Storey RF. Monitoring antiplatelet therapy. Semin Thromb Hemost. 2017;43:311–9.

    Article  CAS  Google Scholar 

  8. Janssen PW, ten Berg JM. Platelet function testing and tailored antiplatelet therapy. J Cardiovasc Transl Res. 2013;6:316–28.

    Article  Google Scholar 

  9. Gross L, Aradi D, Sibbing D. Platelet function testing in patients on antiplatelet medications. Semin Thromb Hemost. 2016;42:306–20.

    Article  CAS  Google Scholar 

  10. Hvas AM, Grove EL. Platelet function tests: Preanalytical variables, clinical utility, advantages, and disadvantages. Methods Mol Biol. 2017;1646:305–20.

    Article  CAS  Google Scholar 

  11. Chlebowski MM, Baltagi S, Carlson M, Levy JH, Spinella PC. Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO. Crit Care. 2020;24:19.

    Article  Google Scholar 

  12. Dubois V, Dincq A-S, Douxfils J, Ick B, Samama C-M, Dogné J-M, et al. Perioperative management of patients on direct oral anticoagulants. Thromb J. 2017;15:14.

    Article  Google Scholar 

  13. Douketis JD, Wang G, Chan N, Eikelboom JW, Syed S, Barty R, Moffat KA, Spencer FA, Blostein M, Schulman S. Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure. J Thromb Haemost. 2016;14:89–97.

    Article  CAS  Google Scholar 

  14. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23:138–43.

    Article  CAS  Google Scholar 

  15. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Investigators A-: Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363:2487–98.

    Article  CAS  Google Scholar 

  16. Douxfils J, Ageno W, Samama C-M, Lessire S, ten Cate H, Verhamme P, Dogne J-M, Mullier F. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018;16:209–19.

    Article  CAS  Google Scholar 

  17. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292–303.

    Article  CAS  Google Scholar 

  18. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P, investigators A. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375:807–15.

    Article  CAS  Google Scholar 

  19. Prexl O, Bruckbauer M, Voelckel W, Grottke O, Ponschab M, Maegele M, et al. The impact of direct oral anticoagulants in traumatic brain injury patients greater than 60-years-old. Scand J Trauma Resusc Emerg Med. 2018;26:20.

    Article  Google Scholar 

  20. Vos PE, Alekseenko Y, Battistin L, Ehler E, Gerstenbrand F, Muresanu DF, et al. Mild traumatic brain injury. Eur J Neurol. 2012;19:191–8.

    Article  CAS  Google Scholar 

  21. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012;107:379–87.

    Article  CAS  Google Scholar 

  22. Wiegele M, Schöchl H, Haushofer A, Ortler M, Leitgeb J, Kwasny O, et al. Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: an Austrian interdisciplinary consensus statement. Crit Care. 2019;23:62.

    Article  Google Scholar 

  23. Connors JM. Testing and monitoring direct oral anticoagulants. Blood. 2018;132(19):2009–15.

    Article  CAS  Google Scholar 

  24. Anderson DR, Morgano GP, Bennett C, Dentali F, Francis CW, Garcia DA, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019;3(23)

    Google Scholar 

  25. Steiner T, Bohm M, Dichgans M, Diener HC, Ell C, Endres M, et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol. 2013;102:399–412.

    Article  CAS  Google Scholar 

  26. Seiffge DJ, Traenka C, Polymeris AA, Thilemann S, Wagner B, Hert L, et al. Intravenous thrombolysis in patients with stroke taking rivaroxaban using drug specific plasma levels: experience with a standard operation procedure in clinical practice. J Stroke. 2017;19:347–55.

    Article  Google Scholar 

  27. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial. Circulation. 2004;110(10):1202–8.

    Article  CAS  Google Scholar 

  28. Steinhubl TR, Berger PB, Tift Mann J, Fry ETA, DeLago A, Wilmer C, Topol EJ et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 20;288(19):2411–20.

    Google Scholar 

  29. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–72.

    Article  CAS  Google Scholar 

  30. Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387–94.

    Article  CAS  Google Scholar 

  31. Rosenstein R, Parra D. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(24):2334.

    CAS  PubMed  Google Scholar 

  32. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.

    Article  CAS  Google Scholar 

  33. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.

    Article  CAS  Google Scholar 

Download references

Acknowledgement

Nil.

Conflicts of Interest

Nil.

Author information

Authors and Affiliations

  1. Nizams Institute of Medical Sciences, Hyderabad, India

    Kavitha Jayaram

Authors
  1. Kavitha Jayaram
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neuroanaesthesiology and Critical Care, All India Institute of Medical Sciences, New Delhi, Delhi, India

    Hemanshu Prabhakar

  2. Anesthesiology and Intensive Care, G B Pant Institute of Medical Education and Research, New Delhi, Delhi, India

    Monica S Tandon

  3. Neuroanaesthesiology and Critical Care, All India Institute of Medical Sciences, New Delhi, Delhi, India

    Indu Kapoor

  4. Neuroanaesthesiology and Critical Care, All India Institute of Medical Sciences, New Delhi, Delhi, India

    Charu Mahajan

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Jayaram, K. (2022). Monitoring Anticoagulation. In: Prabhakar, H., S Tandon, M., Kapoor, I., Mahajan, C. (eds) Transfusion Practice in Clinical Neurosciences. Springer, Singapore. https://doi.org/10.1007/978-981-19-0954-2_38

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-0954-2_38

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-0953-5

  • Online ISBN: 978-981-19-0954-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation